Дата публикации статьи в журнале: 4.07.2019
Название журнала: Американский Научный Журнал, Выпуск: № (26) / 2019, Том: 1, Страницы в выпуске: 16-17
Автор: Andijan , Andijan state medical institute , Dr of science, Head of chair Oncology and Medical Radiology
Автор: Khusniddin Muratov
Andijan , Medical oncology at the Andijan branch center of oncology and radiology,
Автор: Yuri Azizov
Andijan , , Dr of science, head of chair microbiology
Анотация: t we have tried to explain and answer in our work.
Abstract
Every year, more than 1 million new cases of breast cancer are detected in the world, predicting an increase
in the number of cases by 2010 to 1.5 million. In Russia, breast cancer (BC) takes 1st place in the frequency of all
malignant neoplasms in women: 19.8 % Mortality from breast cancer continues to occupy the first place in the
structure of female mortality from cancer and is 17.1% while continuing to grow steadily [8,10]. Despite the last
5 years, indicating the stabilization of the incidence of breast cancer in the age group from 20 to 49 years (51:
100.000), since 2000, there is a global trend towards an increase in the incidence of breast cancer in the group of
young women under the age of 35, cancer is “younger” [2, 6]. At the same time, there is a tendency to increase the
birth rate among women over 30 years old. Consequently, every year there will be an increase in the number of
women in whom breast cancer will be diagnosed during pregnancy or lactation. Today, the incidence of breast
cancer is 1 case per 3,000 pregnant women. Mostly women aged between 32 and 38 are affected [4,9].
DOI:
Данные для цитирования: Dilfuzahon Mamarasulova Khusniddin Muratov Yuri Azizov . BREAST CANCER AND PREGNANCY — HOW TO SOLVE IT. Американский Научный Журнал. Медицинские науки. 4.07.2019; № (26) / 2019(1):16-17.
Список литературы: References
1. Полевая Е.Б., Портной С.М. Рак молочной
железы и беременность // Материалы V Ежегодной
российской онкологической конференции. —
Москва, 27—29 ноября 2011 г. 36-38 с.
2. Amant F, Vandenbroucke T, Verheecke M,
Fumagalli M, Halaska MJ, Boere I, Han S, Gziri MM,
Peccatori F, Rob L et al (2015) Pediatric outcome after maternal cancer diagnosed during pregnancy.
N Engl J Med 373:1824–
1834CrossRefPubMedGoogle Scholar
3. Bamdad S, Bamdad M, Khanlari M, Daneshbod Y, Khademi B (2017) Teratogenic effects of Intravitreal injection of bevacizumab in a pregnant rat
model. Iran J Pharm Res 16:670–
676PubMedPubMedCentralGoogle Scholar
4. Cardonick E, Bhat A, Gilmandyar D, Somer
R (2012) Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann
Oncol 23:3016–3023CrossRefPubMedGoogle
Scholar
5. Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A (2010) Breast cancer during pregnancy: maternal Cardonick E, Gilmandyar D, Somer RA (2012) Maternal and fetal outcomes. Cancer J 16:76–82CrossRefPubMedGoogle
Scholar and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy. Obstet Gynecol 120:1267–1272CrossRefPubMedGoogle Scholar
6. Etwel F, Faught LH, Rieder MJ, Koren G
(2017) The risk of adverse pregnancy outcome after
first trimester exposure to H1 antihistamines: a systematic review and meta-analysis. Drug Saf 40:121–
132CrossRefPubMedGoogle Scholar
7. Han SN, Amant F, Cardonick EH, Loibl S,
Peccatori FA, Gheysens O, Sangalli CA, Nekljudova
V, Steffensen KD, Mhallem Gziri M et al (2017d) Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy.
Breast Cancer Res Treat 2017.
https://doi.org/10.1007/s10549-017-4611-
zPubMedCentralCrossRefPubMedGoogle Scholar
8. Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, Fehm T, Van Calsteren K,
Linn SC, Schlehe B et al (2012) Treatment of breast
cancer during pregnancy: an observational study. Lancet Oncol 13:887–896CrossRefPubMedGoogle
Scholar
9. Murphy CG, Mallam D, Stein S, Patil S,
Howard J, Sklarin N, Hudis CA, Gemignani ML,
Seidman AD (2012) Current or recent pregnancy is
associated with adverse pathologic features but not
impaired survival in early breast cancer. Cancer
118:3254–3259CrossRefPubMedGoogle Scholar
информационное письмо
